Prof. Dr. Dirk Baumjohann
Medical Clinic III for Oncology, Hematology, Immuno-Oncology and Rheumatology
dirk.baumjohann@uni-bonn.de View member: Prof. Dr. Dirk Baumjohann
Trends in cancer
T follicular helper (Tfh) cells provide essential help to B cells for effective antibody-mediated immune responses. Although the crucial function of these CD4 T cells in infection and vaccination is well established, their involvement in cancer is only beginning to emerge. Increased numbers of Tfh cells in Tfh cell-derived or B cell-associated malignancies are often associated with an unfavorable outcome, whereas in various solid organ tumor types of non-lymphocytic origin, their presence frequently coincides with a better prognosis. We discuss recent advances in understanding how Tfh cell crosstalk with B cells and CD8 T cells in secondary and tertiary lymphoid structures (TLS) enhances antitumor immunity, but may also exacerbate immune-related adverse events (irAEs) such as autoimmunity during immune checkpoint blockade (ICB) and cancer immunotherapy.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
PMID: 36642575
Medical Clinic III for Oncology, Hematology, Immuno-Oncology and Rheumatology
dirk.baumjohann@uni-bonn.de View member: Prof. Dr. Dirk Baumjohann